Skip to search formSkip to main contentSkip to account menu

INCB018424

Known as: INCB18424, Oral JAK Inhibitor INCB18424, INCB-018424 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Pyrazoles

Narrower (1)

ruxolitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit… 
Review
2014
Review
2014
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib
There are several reports in LEUKEMIA on the efficacy of JAK2-inhibitors such as ruxolitinib, in persons with MPN-associated… 
2013
2013
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
Janus kinase (JAK) is one of the main upstream activators of signal transducers and activators of transcription (STAT) that are… 
2011
2011
Constitutive NF-κB Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells*
Myeloma cells are dependent on IL6 for their survival and proliferation during the early stages of disease, and independence from… 
2011
2011
Companies hope for kinase inhibitor JAKpot
Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the… 
2008
2008
The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
Background : Myelofibrosis (MF) is characterized by progressive bone marrow dysfunction, extramedullary hematopoiesis, massive… 
2008
2008
The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2
Background: Current evidence links some of the disease manifestations in myelofibrosis (MF) to abnormal cytokines, likely… 
2008
2008
INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).
BACKGROUND: MF is a progressive illness associated with cachexia and weight loss (Mesa et al, Cancer2007;109: 68). These clinical… 
2008
2008
Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement…
Background: Activating mutations in the pseudokinase domain of JAK2 occur at a high frequency in Philadelphia chromosome-negative… 
2007
2007
Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.
Activating mutations in Janus kinase 2 (JAK2) have recently been identified in the majority of Philadelphia chromosome negative… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)